Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Motivational Interviewing-Based Training

NCT06972030 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-09-01
Last updated
2025-05-21

Condition(s) studied

Social ExclusionAggressionBullying of Child

Investigational drug(s) / intervention(s)

Motivational interviewing

Motivational interviewing: After the pre-test, motivational interviewing-based training consisting of six sessions, once a week, will be applied to the students in the experimental group. A pre-test, post-test (after 6 weeks) and control test will be applied to both groups. At the end of the training, training materials will be shared with the students.

Study summary

The middle school period is the period when children begin to experience physical, emotional and social development and try to adapt to psychological changes. In this age group, which is seen as a transition period, the child's academic success and acceptance by peers and friends are also important. The problems experienced during this period can continue in adulthood and children are more likely to experience loneliness, sleep disorders, depression, anxiety, eating disorders, low self-esteem, suicidal thoughts, absenteeism and a decrease in academic success. For this reason, early detection of risky behaviors that threaten children's health and evaluation of health promotion practices are very important issues for child health nursing.

In recent years, peer bullying, aggression and social exclusion have increased and continue to increase in the middle school period, also called early adolescence. For this purpose, a study was needed to identify the situation in middle school students and reduce this negativity. In this respect, it is thought that the study will contribute to the literature. In addition, if the hypotheses of the study are confirmed, it is expected that similar training will be provided in other schools and contribute to the reduction of risky behaviors.

The aim of this study is to determine the effects of motivational interviewing-based education on peer bullying, social exclusion and aggression in secondary school students and to offer suggestions for situations where deficiencies are observed based on the findings obtained.

Eligibility

Sex
ALL
Min age
12 Years
Max age
13 Years
Healthy volunteers
No
Inclusion Criteria: * Being 12-13 years old * Being in one of the 6th and 7th grades of middle school * Having a high score on the ''Peer Bullying Determination Scale'' * Being willing to participate in the research * Not having a communication barrier * The student and their parents having signed the informed consent form. Exclusion Criteria: * Having a low score on the ''Peer Bullying Determination Scale'' * The volunteer not wanting to continue during the research * Encountering any communication barriers during the research * Answering the data collection forms incompletely or incorrectly

Primary outcome measure(s)

  • EFFECTS OF MOTIVATIONAL INTERVIEWING-BASED EDUCATION GIVEN TO SECONDARY SCHOOL STUDENTS ON PEER BULLYING, SOCIAL EXCLUSION AND AGGRESSION — First, a pre-test will be applied to students in both the experimental and control groups. A post-test will be applied to students in the control group after 6 weeks and a control test will be applied 3 months after the post-test. No intervention will be
    In the study, motivational interview-based training will be applied as a nursing intervention. After receiving institutional permission, a pre-test will be applied to students who agree to participate in the study to determine peer bullying. Students whose total scale score is above the average level will be randomly selected and included in the study will be determined. The study will begin after both groups have signed an informed consent form (both students and parents). In collecting research data, the "Introductory Information Form", "Peer Bullying Determination Scale", "Social Exclusion Scale for Children (SESC)", and "Aggression Scale" will be used.

Trial sites (1)

FacilityCityRegionStatus
Mus Alparslan University Muş Muş
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06972030 on ClinicalTrials.gov ↗ ← All trials in Turkey